871259-30-2

Upstream product

• 871259-29-9 t-butyl (2R,3R,4E)-2-benzylamino-3-acetoxyoctadec-4-enoate 
• 871259-09-5 t-butyl (2R,3S)-1-benzyl-3-(pentadec-1-enyl)aziridine-2-carboxylate 

Downstream Products

• 871259-44-8 (1'E,4S,5R)-cis-3-benzyl-5-(pentadec-1-enyl)-4-triisopropylsilanyloxymethyl-1,3-oxazolidin-2-one 
• 871259-37-9 (1'R,2'E,4S)-3-benzyl-4-(1-triisopropylsilanyloxyhexadec-2-enyl)-1,3-oxazolidin-2-one 
• 871259-35-7 (2S,3R,4E)-2-benzylamino-3-triisopropylsilanyloxyoctadec-4-en-1-ol 
• 871259-43-7 (1'E,4S,5R)-cis-3-benzyl-4-hydroxymethyl-5-(pentadec-1-enyl)-1,3-oxazolidin-2-one 
• 871259-33-5 t-butyl (1'E,4R,5R)-cis-3-benzyl-2-oxo-5-(pentadec-1-enyl)-1,3-oxazolidine-4-carboxylate 
• 871259-34-6 t-butyl (2R,3R,4E)-2-benzylamino-3-triisopropylsilanyloxyoctadec-4-enoate 

Relevant academic research and scientific papers

Chirality transfer from guanidinium ylides to 3-alkenyl (or 3-alkynyl) aziridine-2-carboxylates and application to the syntheses of (2R,3S)-3-hydroxyleucinate and D-erythro-sphingosine

Reaction of chiral guanidinium ylides with α,β-unsaturated aldehydes gives 3-(α,β-unsaturated) aziridine-2-carboxylates in high diastereo- and enantioselectivities (up to 93% diastereomeric excess and 98% enantiomeric excess). 3-(1-Methylvinyl)- and 3-[(E)-pentadec-1-enyl]aziridine-2- carboxylates were successfully employed to prepare (2R,3S)-3-hydroxyleucinate and D-erythro-sphingosine, respectively.